Linvoseltamab
- Generic Name
- Linvoseltamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- M3CPC50MZS
- Background
Linvoseltamab is an investigational bispecific antibody. It promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 186
- Registration Number
- NCT06669247
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Dickran Kazandjian, MD
- Target Recruit Count
- 28
- Registration Number
- NCT06376526
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT06369467
- Locations
- 🇺🇸
Emory University- Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT06292780
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇺🇸City of Hope, Duarte, California, United States
🇪🇸Universitary Hospital Son Espases, Palma, Balearic Islands, Spain
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT06140524
- Locations
- 🇪🇸
Hospital Sant Pau, Barcelona, Spain
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Stony Brook University Hospital, Stony Brook, New York, United States
A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
- First Posted Date
- 2023-07-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05955508
- Locations
- 🇪🇸
Hospital Universitario Ramon y Cajal, Madrid, Spain
🇪🇸Clinica Universidad de Navarra - Madrid, Madrid, Spain
🇪🇸University Hospital Doctor Peset, Valencia, Spain
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 132
- Registration Number
- NCT05828511
- Locations
- 🇺🇸
Colorado Blood Cancer Institute/SCRI, Denver, Colorado, United States
🇫🇷Hopital Saint Louis, Paris, France
🇫🇷Hopital Pitié Salpetriere APHP, Paris, France
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 380
- Registration Number
- NCT05730036
- Locations
- 🇧🇪
Ziekenhuis Netwerk Antwerpen Campus Stuivenberg, Antwerp, Belgium
🇵🇱Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Lubelskie, Poland
🇺🇸UCLA, Los Angeles, California, United States
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇺🇸
Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 387
- Registration Number
- NCT03761108
- Locations
- 🇺🇸
University of Miami Hospital/Sylvester Comprehensive, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.